Retatrutide at ADA 2026: TRIUMPH-1 and TRANSCEND-T2D-1 Deliver — and Get Published in The Lancet

The American Diabetes Association (ADA) 2026 Scientific Sessions, held in New Orleans beginning June 5, gave the retatrutide program its biggest stage yet. On Saturday, June 6, a dedicated symposium — “Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Retatrutide” — walked through the full results of two pivotal Phase 3 trials: TRIUMPH-1 in obesity and TRANSCEND-T2D-1 in type 2 diabetes. In a notable vote of confidence, TRANSCEND-T2D-1 was published in The Lancet the same day, moving it from press-release topline to peer-reviewed evidence.

Here is what was actually presented, what changed from the earlier topline numbers, and why the multisystem data may matter more than the headline weight-loss figure.

TRANSCEND-T2D-1: now peer-reviewed in The Lancet

TRANSCEND-T2D-1 enrolled 537 adults with type 2 diabetes across 48 sites in the United States, Mexico, and India, all on metformin, with a mean baseline HbA1c of 7.9%. The published 40-week results:

Between 82% and 89% of participants across the retatrutide doses reached an HbA1c below 7.0% — the standard treatment target — and 75-83% reached the tighter 6.5% threshold. Both HbA1c and weight improved dose-dependently through 12 mg, and no severe hypoglycemia was reported in any arm, an important observation given that retatrutide’s glucagon-receptor activity can raise glucose.

One quiet but instructive detail: the peer-reviewed numbers differ slightly from the March topline. Early estimates had suggested HbA1c reduction might plateau at the 9 mg dose; the published data instead show a clean dose-response, with 12 mg delivering both the best glycemic control and the most weight loss. It is a small reminder of why peer-reviewed publication matters — and why a knowledge base should update to the published figures rather than freeze on the press release.

TRIUMPH-1: the weight-loss headline held up

The obesity trial’s numbers, first reported May 21, were confirmed in the ADA presentation. In 2,339 adults with obesity or overweight plus at least one weight-related comorbidity (no diabetes), mean weight loss at 80 weeks reached:

• 4 mg: -19.0% (-47.2 lbs)
• 9 mg: -25.9% (-64.4 lbs)
• 12 mg: -28.3% (-70.3 lbs)

Nearly half of the 12 mg group (45.3%) lost at least 30% of their body weight, and 65.3% ended the trial with a BMI below 30 — no longer clinically obese. Those figures already made TRIUMPH-1 the most efficacious pivotal obesity readout on record. But the more interesting part of the ADA presentation was what happened to the comorbidities.

The multisystem story: beyond the scale

Because TRIUMPH-1 enrolled people with weight-related comorbidities, it embedded nested “basket” analyses for two high-burden conditions. The results:

A 73.1% reduction in knee-osteoarthritis pain, inside the general obesity trial, echoes the dedicated TRIUMPH-4 trial that reported a 75.8% WOMAC pain reduction at 9 mg. And a 60.6% reduction in the apnea-hypopnea index is squarely in the range that earned tirzepatide its obstructive-sleep-apnea indication through the SURMOUNT-OSA program.

That is the strategic significance. Eli Lilly has signaled that it intends to seek labeling not just for obesity but also for obstructive sleep apnea and knee osteoarthritis. TRIUMPH-1’s nested baskets supply supporting evidence for all three indications from a single pivotal trial — a genuinely efficient regulatory position.

What this means for the timeline

None of the ADA data changed the regulatory calendar. As of July 2026, Eli Lilly has not yet filed a New Drug Application, and industry estimates continue to point to a Q4 2026 filing built on the TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1 packages. A standard 10-to-12-month FDA review would place a possible approval decision in late 2027, or mid-2027 if priority review is granted, with a market launch plausibly in the first half of 2028.

Two core readouts are still outstanding and expected before or around the filing: TRIUMPH-2 (obesity with type 2 diabetes, roughly 1,400 participants) and TRIUMPH-3 (obesity with established cardiovascular disease). Neither had reported as of late July 2026.

The bottom line

ADA 2026 did two things for retatrutide. It moved the diabetes data from topline into the peer-reviewed literature, and it broadened the obesity story from a single number — 28.3% weight loss — into a multisystem case spanning joints and sleep. For a drug that is still investigational and still at least a year from any approval decision, that is about as strong a mid-development showing as the field has seen.

Retatrutide remains investigational and is not approved by the FDA or any regulatory authority. This article summarizes published clinical-trial and conference data for educational purposes; it is not medical advice.